Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript

For the period ending June 30, 2023

August 2, 2023 4:30 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Good afternoon and welcome to the Sarepta Therapeutics Second Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded.

At this time. I'll turn the call over to Francesca Nolan, Executive Director, Investor Relations and Corporate Communications. Please go ahead.

Francesca Nolan

Thank you, Jonathan. And thank you all for joining today's call. Earlier this afternoon, we released our financial results for the second quarter 2023. The press release is available on our website at sarepta.com and our 10-Q was filed with the Securities and Exchange Commission this afternoon.

Joining us on the call today, are Doug Ingram; Ian Estepan; Dallan Murray and Dr. Louise Rodino-Klapac. After our further remarks, we'll open the call for Q&A.

I'd like to know that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slides on the webcast which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties many of which are beyond Sarepta's control. Actual results can materially differ from the forward-looking statements and any such risks can materially adversely affect the business, the results of operations and trading prices for Sarepta's common stock.

For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent quarterly report on form 10-Q filed with the SEC, as well as the company's other SEC filings. The company does not undertake any obligation to publicly update forward-looking statement, including any financial projections provided today based on subsequent events or circumstances.

And now we'll turn the call over to our president and CEO, Doug Ingram, who will provide an overview of our recent product progress. Doug?

Doug Ingram

Thank you, Fran. Good afternoon, and thank you for joining our second quarter 2023 financial results conference call. The second quarter of this year was perhaps the most consequential period in the long consequential history of Sarepta. For families living with Duchenne, it was far more than that still. Buddy Cassidy living with Duchenne and then an ELEVIDYS advisory committee member shared the collective view of the Duchenne community on the June approval in words far more eloquent than I could possibly muster.